Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE: 300434)
Health Care · Pharmaceuticals · CN
CN¥11.84
-7.36% today · +10.2% 1Y
Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE: 300434) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $707.58M and employs 1,794 people.
Over the last twelve months the share price has gained 10.2%, trading between 8.58 and 13.56.
Tweenvest scores Sichuan Goldstone Asia Pharmaceutical Inc. across four factors: quality 68/100, value 50/100, growth 23/100, dividend 47/100. Its strongest factor is quality.
300434 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $707.58M
- Revenue (TTM)
- $156.35M
- P/E
- 25.55
- EPS
- 0.46
- Dividend yield
- 0.69%
- Beta (5Y)
- 0.50
- 52-week high
- CN¥13.56
- 52-week low
- CN¥8.58
- Avg volume (3M)
- —
- Shares outstanding
- 401.74M
- Employees
- 1,794
- Next earnings
- —
About Sichuan Goldstone Asia Pharmaceutical Inc.
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment. It also imports and exports spare parts, raw, and auxiliary materials. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 1962 and is based in Hangzhou, China.
- ISIN
- CNE100001YX5
- Founded
- 1962
- Listed since
- Apr 30, 2015
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.19 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.00 | +0.28% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.00 | +0.29% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.